Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis Article Swipe

PDF

Related Concepts

Golimumab Medicine Ulcerative colitis Internal medicine Confidence interval Interquartile range Colectomy Retrospective cohort study Cohort study Surgery Adalimumab Tumor necrosis factor alpha Disease

Carlos Taxonera , Cristina Rodríguez , Federico Bertoletti , Luís Menchén , Julia Arribas , Mónica Sierra , Lara Arias , Pilar Martínez-Montiel , Alba Juan Juan , Eva Iglesias , Alicia Algaba , Noemí Manceñido , Montserrat Rivero , Manuel Barreiro‐de Acosta , Pilar López Serrano , Federico Argüelles‐Arias , Ana Gutiérrez , David Busquets , Javier P. Gisbert , David Olivares , Marta Calvo , Cristina Alba ·

YOU? · · 2017 · Open Access · · DOI: https://doi.org/10.1097/mib.0000000000001144 · OA: W2726676976

In this real-life cohort of patients with UC, golimumab therapy was effective for inducing and maintaining clinical response. Although anti-TNF-naive patients had better outcomes, golimumab was also effective in anti-TNF-experienced patients. Only the patients given golimumab after previous failure of 2 anti-TNF agents had significantly worse outcomes. Golimumab dose escalation was beneficial and safe.